Investors
Investment case
Why should you invest in Enzymatica?
✓ Unique barrier technology - Patented enzyme-based barrier technology with in-house production and control over quality and supply.
✓ Strong scientific evidence - ColdZyme is MDR-certified and supported by clinical research and peer-reviewed scientific studies.
✓ Favorable market trends - Growing focus on self-care and health is driving demand for effective, evidence-based products.
✓ Satisfied consumers - ColdZyme has a strong consumer base and high repurchase intent among users.
✓ Scalable business model - International expansion through established partners enables growth with limited capital requirements.
✓Driven and multidisciplinary team - Enzymatica combines scientific, regulatory and commercial expertise to drive continued growth.